OncoMatch

OncoMatch/Clinical Trials/NCT06609005

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Is NCT06609005 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies INV-9956 for advanced metastatic castration resistant prostate cancer.

Phase 1/2RecruitingShenzhen Ionova Life Sciences Co., Ltd.NCT06609005Data as of Jun 2026Location: United States · China

Treatment: INV-9956This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

INV-9956

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Male only

Prior therapy

Min 2 prior lines

Must have received: taxane

Received at least one prior line of taxane-based chemotherapy

Must have received: hormonal AR targeted therapy (abiraterone, enzalutamide)

at least one line of hormonal AR targeted therapy (eg, abiraterone, enzalutamide)

Lab requirements

Blood counts

adequate marrow function

Kidney function

adequate kidney function

Liver function

adequate liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Honor Health · Scottsdale, Arizona
  • Hoag Family Cancer Institute · Newport Beach, California
  • UC Irvine Medical Center · Orange, California
  • Next Oncology - Houston · Houston, Texas
  • UT Health · San Antonio, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06609005 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received taxane and hormonal AR targeted therapy.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify